|Bid||56.25 x 900|
|Ask||58.00 x 1100|
|Day's Range||52.81 - 57.84|
|52 Week Range||49.26 - 142.11|
|Beta (5Y Monthly)||0.34|
|PE Ratio (TTM)||26.42|
|Earnings Date||Aug. 02, 2021 - Aug. 06, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||101.71|
A day after its stock took a 13% bath following the release of fourth-quarter results, Haemonetics (NYSE: HAE) bounced back on Friday. Friday saw five financial services companies tracking Haemonetics stock adjust their views. The analysts at four of those five -- Morgan Stanley, JMP Securities, Needham & Company, Jefferies, and CJS Securities -- all lowered their price targets.
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'd...
Investors were not kind to Haemonetics (NYSE: HAE) on Thursday, trading the stock down by more than 13%. The sell-off occurred in the wake of the blood and plasma collection systems company's 2021 earnings release for the fiscal fourth quarter of 2021. The quarter saw Haemonetics earn $221 million in revenue, down 6% on a year-over-year basis.